TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH
Brief Summary: This is a controlled study to determine the effectiveness and safety of ethyl icosapentate (EPA-E) in the treatment of adult patients with non-alcoholic steatohepatitis (NASH).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsule | Arm Label: EPA-E 1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Arm Label: EPA-E 2700 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 1800 mg/day | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 2700 mg/day
B: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention | Arm Label: Life style intervention, pioglitazone; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention, Drug: pioglitazone | Arm Label: Life style intervention, berberine; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention, Drug: berberine | Intervention Type: BEHAVIORAL; Name: Life style intervention; Assigned to Arm(s): Life style intervention, berberine, Life style intervention, pioglitazone, Lifestyle intervention | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Life style intervention, pioglitazone | Intervention Type: DRUG; Name: berberine; Assigned to Arm(s): Life style intervention, berberine
C: Arm Label: VSL#3 placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: VSL#3 placebo | Arm Label: VSL#3 active probiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: VSL#3 active probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: VSL#3 active probiotic; Assigned to Arm(s): VSL#3 active probiotic | Intervention Type: OTHER; Name: VSL#3 placebo; Assigned to Arm(s): VSL#3 placebo
D: Arm Label: caffeine and chlorogeinc acid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: caffeine and chlorogenic acid | Arm Label: caffeine; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: caffeine | Arm Label: chlorogenic acid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: chlorogenic acid | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: caffeine and chlorogenic acid; Assigned to Arm(s): caffeine and chlorogeinc acid | Intervention Type: DIETARY_SUPPLEMENT; Name: caffeine; Assigned to Arm(s): caffeine | Intervention Type: DIETARY_SUPPLEMENT; Name: chlorogenic acid; Assigned to Arm(s): chlorogenic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH
Brief Summary: This is a controlled study to determine the effectiveness and safety of ethyl icosapentate (EPA-E) in the treatment of adult patients with non-alcoholic steatohepatitis (NASH).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega 3 (n-3 PUFA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3 (n-3 PUFA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsule | Arm Label: EPA-E 1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Arm Label: EPA-E 2700 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 1800 mg/day | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 2700 mg/day
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Flaxseed; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Flaxseed; Assigned to Arm(s): Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: DHA (Docosahexaenoic Acid) | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DHA (Docosahexaenoic Acid); Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH
Brief Summary: This is a controlled study to determine the effectiveness and safety of ethyl icosapentate (EPA-E) in the treatment of adult patients with non-alcoholic steatohepatitis (NASH).


Options:
A: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil
B: Intervention Type: DRUG; Name: Triomar™ (omega-3 fatty acids); Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsule | Arm Label: EPA-E 1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Arm Label: EPA-E 2700 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 1800 mg/day | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 2700 mg/day
D: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Synbiotic | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH
Brief Summary: This is a controlled study to determine the effectiveness and safety of ethyl icosapentate (EPA-E) in the treatment of adult patients with non-alcoholic steatohepatitis (NASH).


Options:
A: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: DHA (Docosahexaenoic Acid) | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DHA (Docosahexaenoic Acid); Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsule | Arm Label: EPA-E 1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Arm Label: EPA-E 2700 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 1800 mg/day | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 2700 mg/day
C: Arm Label: Lower fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Lower carbohydrate diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Walnut-rich diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Intervention Type: BEHAVIORAL; Name: Weight loss; Assigned to Arm(s): Lower carbohydrate diet, Lower fat diet, Walnut-rich diet
D: Arm Label: Omega 3 recipient arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega 3 Fish Oil supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega 3 Fish Oil supplements; Assigned to Arm(s): Omega 3 recipient arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH
Brief Summary: This is a controlled study to determine the effectiveness and safety of ethyl icosapentate (EPA-E) in the treatment of adult patients with non-alcoholic steatohepatitis (NASH).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsule | Arm Label: EPA-E 1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Arm Label: EPA-E 2700 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 1800 mg/day | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 2700 mg/day
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Epanova™ (Omega-3 Free Fatty Acids); Assigned to Arm(s): N/A
D: Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MIPARC - Multilevel Intervention for Physical Activity in Retirement Communities
Brief Summary: The purpose of this study was to assess whether a 6-month multilevel physical activity intervention can significantly increase physical activity levels in sedentary adults, 65 and older, living in Continuing Care Retirement Communities (CCRCs).

Sedentary residents (N=307) in 11 CCRCs received the multilevel MIPARC intervention or a control health education program for 6 months. A group randomized control design was employed with site as the unit of randomization. The intervention was delivered through group sessions, phone calls, printed materials, tailored signage and mapping and targeted peer led advocacy efforts.


Options:
A: Arm Label: MIPARC intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity, Behavioral: Group educational sessions, Behavioral: Phone counseling call, Behavioral: Peer Mentoring, Behavioral: Policy Change, Behavioral: Support, Behavioral: Tailored environmental resources | Arm Label: Health Education Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group educational sessions, Behavioral: Health check phone call, Behavioral: Pedometer | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): MIPARC intervention | Intervention Type: BEHAVIORAL; Name: Group educational sessions; Assigned to Arm(s): MIPARC intervention | Intervention Type: BEHAVIORAL; Name: Phone counseling call; Assigned to Arm(s): MIPARC intervention | Intervention Type: BEHAVIORAL; Name: Peer Mentoring; Assigned to Arm(s): MIPARC intervention | Intervention Type: BEHAVIORAL; Name: Policy Change; Assigned to Arm(s): MIPARC intervention | Intervention Type: BEHAVIORAL; Name: Support; Assigned to Arm(s): MIPARC intervention | Intervention Type: BEHAVIORAL; Name: Tailored environmental resources; Assigned to Arm(s): MIPARC intervention | Intervention Type: BEHAVIORAL; Name: Group educational sessions; Assigned to Arm(s): Health Education Control | Intervention Type: BEHAVIORAL; Name: Health check phone call; Assigned to Arm(s): Health Education Control | Intervention Type: BEHAVIORAL; Name: Pedometer; Assigned to Arm(s): Health Education Control
B: Arm Label: REACH Participant Course; Type: EXPERIMENTAL; Interventions: Behavioral: REACH | Intervention Type: BEHAVIORAL; Name: REACH; Assigned to Arm(s): REACH Participant Course
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: Behavioral: website assess | Intervention Type: BEHAVIORAL; Name: website assess; Assigned to Arm(s): Control group
D: Arm Label: I-STAND; Type: EXPERIMENTAL; Interventions: Behavioral: I-STAND | Arm Label: Healthy Living; Type: ACTIVE_COMPARATOR; Interventions: Other: Healthy Living | Intervention Type: BEHAVIORAL; Name: I-STAND; Assigned to Arm(s): I-STAND | Intervention Type: OTHER; Name: Healthy Living; Assigned to Arm(s): Healthy Living

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Restoration of Bowel Function After Laparoscopic Colorectal Surgery: Effect of Intravenous Lidocaine
Brief Summary: Patients receiving perioperative intravenous lidocaine, post operative restoration of bowel movement will be faster and decrease pain intensity, opioid consumption and side effects, length of hospital stay; probably as a result of a significant opioid sparing and attenuated inflammatory response.


Options:
A: Arm Label: LIDOCAINE group; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Arm Label: Epidural group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Thoracic epidural block | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): LIDOCAINE group | Intervention Type: PROCEDURE; Name: Thoracic epidural block; Assigned to Arm(s): Epidural group
B: Arm Label: Lidocaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lidocaine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Lidocaine
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lidocaine; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Lidocaine
D: Arm Label: Group L; Type: EXPERIMENTAL; Interventions: Drug: Systemic intravenous lidocaine infusion | Arm Label: Group C; Type: PLACEBO_COMPARATOR; Interventions: Drug: normal saline infusion | Intervention Type: DRUG; Name: Systemic intravenous lidocaine infusion; Assigned to Arm(s): Group L | Intervention Type: DRUG; Name: normal saline infusion; Assigned to Arm(s): Group C

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Carvedilol Post-intervention Long-term Administration in Large-scale Randomized Controlled Trial
Brief Summary: The purpose of this study is to evaluate whether beta-blocker therapy improves 6-year clinical outcomes in patients with ST-segment elevation acute myocardial infarction and preserved left ventricular ejection fraction after primary percutaneous coronary intervention.


Options:
A: Intervention Type: DRUG; Name: clopidogrel (SR25990); Assigned to Arm(s): N/A
B: Arm Label: Beta-blocker adherence after an AMI; Type: EXPERIMENTAL; Interventions: Behavioral: Beta-blocker adherence after an AMI | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Beta-blocker adherence after an AMI; Assigned to Arm(s): Beta-blocker adherence after an AMI
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol controlled release (CR) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metoprolol controlled release (CR); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: Beta-blocker; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carvedilol | Arm Label: Non Beta-blocker; Type: ACTIVE_COMPARATOR; Interventions: Drug: No Carvedilol | Intervention Type: DRUG; Name: Carvedilol; Assigned to Arm(s): Beta-blocker | Intervention Type: DRUG; Name: No Carvedilol; Assigned to Arm(s): Non Beta-blocker

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Carvedilol Post-intervention Long-term Administration in Large-scale Randomized Controlled Trial
Brief Summary: The purpose of this study is to evaluate whether beta-blocker therapy improves 6-year clinical outcomes in patients with ST-segment elevation acute myocardial infarction and preserved left ventricular ejection fraction after primary percutaneous coronary intervention.


Options:
A: Arm Label: Early metoprolol initiation strategy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Injectable (i.v.) metoprolol tartrate (up to 15 mg). | Arm Label: Delayed metoprolol initiation strategy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Injectable (i.v.) metoprolol tartrate (up to 15 mg).; Assigned to Arm(s): Early metoprolol initiation strategy
B: Arm Label: Beta-blocker; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carvedilol | Arm Label: Non Beta-blocker; Type: ACTIVE_COMPARATOR; Interventions: Drug: No Carvedilol | Intervention Type: DRUG; Name: Carvedilol; Assigned to Arm(s): Beta-blocker | Intervention Type: DRUG; Name: No Carvedilol; Assigned to Arm(s): Non Beta-blocker
C: Intervention Type: DRUG; Name: clopidogrel and metoprolol; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: N/A; Interventions: Other: Blood sample | Intervention Type: OTHER; Name: Blood sample; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The assessment intends to investigate the efficacy of psychosocial counseling for the treatment of help seeking individuals with psychosocial problems in Mazar-e-Sharif, Afghanistan. Treatment was administered by local counselors who had received specific education and training


Options:
A: Arm Label: Psychosocial counseling; Type: N/A; Interventions: N/A | Arm Label: Medication; Type: N/A; Interventions: N/A
B: Arm Label: Waitlist+EducAid; Type: ACTIVE_COMPARATOR; Interventions: Other: EducAid educational programming | Arm Label: Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: YRI only; Type: EXPERIMENTAL; Interventions: Behavioral: YRI, Other: EducAid educational programming | Arm Label: YRI+EducAid; Type: EXPERIMENTAL; Interventions: Behavioral: YRI, Other: EducAid educational programming | Intervention Type: BEHAVIORAL; Name: YRI; Assigned to Arm(s): YRI only, YRI+EducAid | Intervention Type: OTHER; Name: EducAid educational programming; Assigned to Arm(s): Waitlist+EducAid, YRI only, YRI+EducAid
C: Arm Label: 1 Interpersonal Psychotherapy (IPT); Type: EXPERIMENTAL; Interventions: Behavioral: Interpersonal Psychotherapy | Arm Label: 2 Prolonged Exposure (PE); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prolonged Exposure Therapy | Arm Label: 3 Relaxation therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Relaxation Therapy | Intervention Type: BEHAVIORAL; Name: Interpersonal Psychotherapy; Assigned to Arm(s): 1 Interpersonal Psychotherapy (IPT) | Intervention Type: BEHAVIORAL; Name: Prolonged Exposure Therapy; Assigned to Arm(s): 2 Prolonged Exposure (PE) | Intervention Type: BEHAVIORAL; Name: Relaxation Therapy; Assigned to Arm(s): 3 Relaxation therapy
D: Arm Label: TF-CBT; Type: EXPERIMENTAL; Interventions: Behavioral: TF-CBT | Arm Label: Waiting List control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: TF-CBT; Assigned to Arm(s): TF-CBT

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The assessment intends to investigate the efficacy of psychosocial counseling for the treatment of help seeking individuals with psychosocial problems in Mazar-e-Sharif, Afghanistan. Treatment was administered by local counselors who had received specific education and training


Options:
A: Arm Label: Mind-Body Skills Groups; Type: EXPERIMENTAL; Interventions: Behavioral: Mind-Body Skills Groups | Arm Label: Delayed Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mind-Body Skills Groups; Assigned to Arm(s): Mind-Body Skills Groups
B: Arm Label: PRIME; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PRIME/mhGAP | Arm Label: PRIME+RESHAPE; Type: EXPERIMENTAL; Interventions: Behavioral: RESHAPE, Behavioral: PRIME/mhGAP | Intervention Type: BEHAVIORAL; Name: RESHAPE; Assigned to Arm(s): PRIME+RESHAPE | Intervention Type: BEHAVIORAL; Name: PRIME/mhGAP; Assigned to Arm(s): PRIME, PRIME+RESHAPE
C: Arm Label: Group problem management plus; Type: EXPERIMENTAL; Interventions: Behavioral: Group problem management plus | Arm Label: Enhanced treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced treatment as usual | Intervention Type: BEHAVIORAL; Name: Group problem management plus; Assigned to Arm(s): Group problem management plus | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual; Assigned to Arm(s): Enhanced treatment as usual
D: Arm Label: Psychosocial counseling; Type: N/A; Interventions: N/A | Arm Label: Medication; Type: N/A; Interventions: N/A

Answer: D